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‘Sex’ in the cancer cell
Inam J. Lafta, Helen E. Bryant, and Alastair S. H. Goldman
The development of better tools for diagnosis and 
more accurate prognosis of cancer includes the search 
for biomarkers; molecules whose presence, absence 
or change in quantity or structure is associated with a 
particular tumour or prognosis/therapeutic outcome. 
While biomarkers need not be functionally relevant, if 
their expression influences cell transformation or cancer 
cell survival, then they could also provide new targets for 
therapeutic drugs.
In recent years attention has been applied to a group 
of proteins known as cancer testis antigens (CT antigens) 
[1]. These proteins are products of genes whose expression 
was originally thought normally to be confined to the 
testis, yet they are expressed in tumour cells. CT genes are 
bound to serve a wide array of roles in the testes, which 
have many highly differentiated cell types and, uniquely, 
the specialised role of bearing a germline with cells 
passing through meiosis.
Early on, autologous typing of patient antibodies 
and T-cells demonstrated CT gene expression in tumours, 
the first example being MAGEA1 in melanoma [1]. 
Later serological screening of cDNA expression libraries 
identified further CT antigens including the meiosis 
specific synaptonemal complex protein 1 (SCP1) in 
malignant gliomas, breast, renal cell, and ovarian 
cancer [1]. More recently high throughput technologies 
have gradually increased the number of apparent CT 
antigens/genes [1,2]. CT gene expression has been used 
as a prognostic/stratification tool to identify aggressive 
metastasis prone lung cancer [3] and chemo-resistance 
[4]. But wider analysis of gene expression suggests that 
activity of many CT is not wholly confined to the testis. 
Some CT genes are expressed in the central nervous 
system, and others are expressed in a range of normal 
tissues (see [5]). So, the CT label has been unfortunately 
applied as misnomer to some antigens/genes, and the 
generic group is probably not suitable as biomarkers. 
But, is there a subset of so-called CT genes that really are 
normally testis specific?
Following the discovery that ~25% of Drosophila 
genes misregulated during malignant brain growth are 
required in the germ line [6], Feichtinger, et al reasoned 
that the germline subset of testis expressing genes might 
be more reliably silent in normal somatic cells [5]. They 
termed these meiotic cancer testis (meiCT) genes. The 
functional classification of meiCTs is cautious, as it results 
from examining gene expression in isolated mouse meiotic 
cells. Mammalian meiotic function was not demonstrated 
for all genes, and there could have been non-meiotic cell 
contamination. Indeed, they found some putative meiCT 
genes, which are meiosis specific in lower eukaryotes, to 
be expressed in somatic tissue. However, other meiotic 
genes such as RAD21L and SMC1-beta appeared tightly 
restricted to the testis. A wider bioinformatic screen of 
putative meiCT genes using EST data, backed up by RT-
PCR experiments, provided a larger group of 17 genes that 
appear to be expressed only in testes and cancer cell lines 
or tumour tissue. A further 5 genes were also expressed in 
the CNS, meaning their corresponding proteins should not 
normally be circulating around the body, so they remain 
potential biomarkers. More recently the same group 
have published an extension their work in Oncoscience 
[7]. They used a bioinformatics pipline to identify more 
putative meiCT genes followed by RT-PCR validation on 
a range of normal tissues, cancer cell lines and tumour 
tissues [7]. This identified a further 19 meiCT genes 
likely to be expressed in more than one tumour type. In 
both studies, a meta-analysis of patient microarray sets 
delivered positive hits for meiCTs, including for some that 
originally gave RT-PCR negative results in limited tumour 
samples. 
Two aspects of the results are especially exciting. 
Firstly, a large proportion of positive hits indicated meiCT 
gene expression in ovarian cancer, for which potential CT 
biomarkers have been identified before (see [7]). Similar 
meiCT gene expression between testes and ovaries might 
seem like an obvious result since both organs undergo 
meiosis. But functional activity of the tesovarian and testes 
germlines does not simply overlap. Spermatogenesis is 
restricted to the adult, while oogenesis begins in the foetal 
ovaries, and then completes one cell at a time, monthly, in 
the adult. So association of meiCT gene expression with 
ovarian cancer hints at the possibility that these genes 
become deregulated in cancerous ovaries, or possibly 
they contribute to tumourogenesis. In either case, MeiCT 
genes/antigens could make good biomarkers in ovarian 
cancer.
Secondly, the expression of some meiCT genes 
makes oncogenic sense. For example the ADAM2 protein 
has a disintegrin and metalloprotease domain and is 
associated with cell-cell interactions (see [7]). These are 
properties that might well correlate with the invasive and 
metastatic characteristics of cancer cells. This is highly 
speculative as the functional relevance of meiCTs is yet 
to be confirmed, but it is worth considering that there is 
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a prospect of some meiCT antigens not only serving as 
biomarkers but also having oncogenic properties, which 
could become targets for drug therapy. So, with more work 
and some luck, we may yet find that ‘sex’ in the cancer 
cells provides us with new tools to fight cancer.  
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